GHGeorgios Hatzichristodoulou

Georgios Hatzichristodoulou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Georgios Hatzichristodoulou has a total of 412 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Implantation eines Penisimplantates mit simultaner Korrektur der Penisverkrümmung bei Patienten mit Morbus Peyronie

    by Georgios Hatzichristodoulou

    Zusammenfassung: Die operative Therapie der Induratio penis plastica bleibt der Goldstandard zur Korrektur der Penisverkrümmung. Bei Patienten mit schwerer erektiler Dysfunktion ist die Implantation einer Penisprothese angezeigt. Eine Korrektur der residuellen Penisverkrümmung kann durch Plaqueinzision und Grafting erfolgen. Das Kollagenvlies TachoSil (Corza Medical, MA, USA) stellt ein zuverlässiges Graft mit vielversprechenden Ergebnissen dar. 2018 veröffentlichte Hatzichristodoulou erstmals seine neue Technik der Plaqueinzision und Grafting mit TachoSil zur Korrektur der residuellen Penisverkrümmung während der Penisprothesenimplantation (PICS Technik). Seitdem hat sich diese Methode verbreitet und wird mittlerweile von vielen Chirurgen weltweit eingesetzt. In der vorliegenden narrativen Übersichtsarbeit werden alle Veröffentlichungen berücksichtigt, die den Einsatz von TachoSil nach Plaqueinzision zur Korrektur der residuellen Penisverkrümmung beschreiben. TachoSil ist selbstklebend, was es einzigartig, sicher und ideal für diese Indikation macht. Die in der Literatur beschriebenen Ergebnisse dieser Technik sind ausgezeichnet. Es werden jedoch zusätzliche Daten mit größeren Patientenzahlen und Langzeitbeobachtungen benötigt.

  • Correction: Penile prosthesis implantation: a systematic review of intraoperative and postoperative complications

    by Andrea Cocci, Paolo Capogrosso, Suks Minhas, Carlo Bettocchi, Luca Boeri, Joana Carvalho, Nusret Can Cilesiz, Giovanni Corona, Konstantinos Dimitropoulos, Murat Gül, et al.


  • Penile prosthesis implantation: a systematic review of intraoperative and postoperative complications

    by Andrea Cocci, Paolo Capogrosso, Suks Minhas, Carlo Bettocchi, Luca Boeri, Joana Carvalho, Nusret Can Cilesiz, Giovanni Corona, Konstantinos Dimitropoulos, Murat Gül, et al.

    Erectile dysfunction (ED) is the most frequently reported male sexual dysfunction. Penile prosthesis implantation (PPI) is an effective solution for patients with medically refractory ED. Despite advancements in surgical techniques and device technology, detailed evidence on PPI complication rates is limited. A systematic review was conducted following PRISMA guidelines, including literature from Medline, Embase, Cochrane Libraries, and clinicaltrial.gov from 2000 to October 2024. Eligible studies included randomized controlled trials (RCTs), non-randomized comparative studies, and case series with ≥5 participants. Adult male patients (≥18 years) undergoing PPI for ED, Peyronie’s disease, or priapism were considered. Eligible interventions included malleable and hydraulic (two- or three-piece) prosthesis implantation, device explantation and reimplantation, and PPI combined with penile curvature correction. Primary outcomes were intraoperative and postoperative complication rates. Of the 1370 studies initially identified, 151 met inclusion criteria, encompassing a total of 92,777 patients. Device infections were reported in 103 studies, with rates ranging from 0.03–14.3%, predominantly under 5%. Erosion rates spanned 0.02–32.5%, with most studies reporting rates below 5%. Mechanical failure rates were highly variable, exceeding 15% in about half the studies with follow-up periods of 5 to 11 years. Intraoperative complications such as urethral injury and corporeal perforation were uncommon but occurred more frequently in patients with severe fibrosis, including those with priapism. Neurological comorbidities were associated with an elevated risk of mechanical failure, while diabetic patients did not exhibit a significantly increased infection risk compared to the general population. Modern techniques and coated devices have reduced infection and erosion rates. However, mechanical failure remains a concern, emphasizing the need for technological advancements. Tailored device selection and comprehensive pre- and postoperative management are critical to reducing revision rates and improving outcomes. Future research should address gaps in surgical approach optimization and complication management.


  • Simultaneous penile prosthesis placement and collagen fleece (TachoSil) grafting. Where do we stand in 2024?

    by Georgios Hatzichristodoulou

    Surgical therapy of Peyronie’s disease is the gold standard for correction of the associated penile curvature. In patients with co-existing erectile dysfunction, not responding to medical/conservative treatment, penile prosthesis implantation is indicated and recommended. Severe residual curvature in these cases can be addressed by plaque incision and grafting. The novel collagen fleece TachoSil® (Corza Medical, MA, USA) has emerged as a reliable and robust graft for this purpose, with favorable results. Hatzichristodoulou was the first to publish his new technique of plaque incision and grafting with TachoSil® for residual curvature correction during penile prosthesis implantation in 2018 (PICS Technique). Since then, this technique was adopted and used by various surgeons. In the current narrative review all publications using this novel graft after plaque incision for residual curvature correction will be presented and respective results discussed. Moreover, the surgical technique will be highlighted in detail. The TachoSil® has self-adhesive properties which make it unique and the ideal graft for this indication. Results of the studies on this topic, that are available so far, are excellent. The technique is safe. However, data from more patients and even more long-term follow-up results of patients treated with this technique and graft are requested.


  • Factors Affecting Implant Length in Primary Inflatable Penile Prosthesis Placement

    by Jake A. Miller, Muhammed Hammad, Eliad Amini, Robert Andrianne, Arthur L. Burnett, Kelli Gross, Martin S. Gross, Georgios Hatzichristodoulou, James Hotaling, Tung-Chin Hsieh, et al.


  • Does climate impact inflatable penile prosthesis infection (IPP) risk? Assessment of temperature and dew point on IPP infections

    by David W Barham, Nikolaos Pyrgidis, Eliad Amini, Muhammed Hammad, Jake Miller, Robert Andrianne, Arthur L Burnett, Kelli Gross, Georgios Hatzichristodoulou, James Hotaling, et al.

    Background: Variations in climate have been associated with a greater risk of surgical site infections, urinary tract infections, and changes in the skin microbiome; however, limited data exist on the impact of climate on inflatable penile prosthesis (IPP) infections. Aim: We sought to evaluate the impact of climate on the risk of IPP infections in a large international, multicenter cohort. Methods: We performed a multi-institutional, retrospective study of patients undergoing IPP surgery. We then evaluated whether the month or season, during which surgery was performed, affected device infections. Implant infections were defined as infections requiring device explantation. A univariate logistic regression analysis was undertaken. Outcomes: Our primary outcome was implant infection. Results: A total of 5289 patients with a mean age of 62.2 ± 10.8 years received IPP placement. There was a fairly even distribution of implants performed in each season. A total of 103 (1.9%) infections were recorded. There were 32 (31.1%) IPP infections in patients who underwent surgery in the summer, followed by 28 (27.2%) in the winter, 26 (25.2%) in the spring, and 17 (16.5%) in the fall. No statistically significant differences were recorded in terms of season (P = .19) and month (P = .29). The mean daily temperature (P = .43), dew point (P = .43), and humidity (P = .92) at the time of IPP placement was not associated with infection. Clinical Implications: These findings provide reassurance to prosthetic urologists that infection reduction strategies do not need to be tailored to local climate. Strengths and Limitations: Climate data were not directly recorded for each hospital, but rather based on the monthly averages in the city where the surgery was performed. Conclusion: The climate at time of IPP placement and time of year of surgery is not associated with IPP infection risk.


  • First worldwide correction of ventral Peyronie’s disease utilizing rigicon inflatable penile prosthesis combined with plaque incision & grafting with collagen fleece (PICS-technique) for residual curvature

    by Georgios Hatzichristodoulou, Mehmet Hamza Gültekin, Hamdi Özkara, Emre Akkus

    Adjunctive residual curvature correction by plaque incision and grafting with a sutureless graft during inflatable penile prosthesis (IPP) implantation in patients with Peyronie’s disease (PD) is our preferred technique. The PICS Technique (Penile Implant in Combination with the Sealing Technique) uses a self-adhesive collagen fleece (TachoSil®, Corza Medical, MA, USA) to cover the defect after plaque incision. The graft does not require sutures improving operative speed and avoiding needle stick of the implant cylinders. In this article, we present the first known application worldwide of a Rigicon Infla10® X (Rigicon, Ronkonkoma, NY, USA) device to Peyronie’s ventral curvature. The patient’s residual curvature of 80° after implantation was corrected by PICS through an additional subcoronal incision. At the conclusion of surgery, the penis was totally straight and rigid. No intra- and postoperative complications occurred. At the early follow-up of 12 weeks postoperatively, the patient was able to inflate and deflate the device and sexual intercourse was possible. A combination of the Rigicon Infla10® X and the PICS Technique represents a safe and successful approach for residual curvature correction during IPP in patients with ventral Peyronie’s curvature. The Rigicon Infla10® X device showed excellent rigidity, and controlled expansion of the X cylinders means it can be used with the PICS Technique without restrictions. Early results are promising. Long-term follow-up and more patients are needed.


  • Open Access

    Avelumab in metastatic collecting duct carcinoma of the kidney: a case report

    by Nikolaos Pyrgidis, Ioannis Sokolakis, Gena Haltmair, Vitus Heller, Georgios Hatzichristodoulou

    Collecting duct carcinoma (CDC) of the kidney is associated with an aggressive course, limited response to treatment, and poor prognosis. Platinum-based chemotherapy is currently recommended as the first-line treatment in patients with metastatic CDC. Accumulating evidence supports the use of immunotherapy with checkpoint inhibitors as second-line therapy. In this case report, we describe the first case of avelumab administration due to disease progression during chemotherapy with gemcitabine and cisplatin in a Caucasian, 71-year-old man presenting with multiple metastases due to CDC of the kidney. The patient initially responded well to four cycles of chemotherapy and his performance status improved. After two additional chemotherapy cycles, the patient presented with new bone and liver metastases (mixed response to chemotherapy with an overall 6-month progression-free survival). We offered him avelumab as a second-line treatment in this setting. The patient received a total of three cycles of avelumab. The disease remained stable (no new metastases during treatment with avelumab), and the patient developed no complications. To alleviate his symptoms, radiation therapy for the bone metastases was decided. Despite successful radiation of the bone lesions and further improvement of symptoms, the patient developed hospital-acquired pneumonia and died approximately ten months after the initial diagnosis of CDC. Our findings suggest that the applied treatment modality with gemcitabine and cisplatin chemotherapy followed by avelumab was effective in terms of both progression-free survival and quality of life. Still, further studies assessing the use of avelumab in this setting are mandatory.